Gilead人民的希望初步试验失败，三期中症试验效果不彰

[寻找尼莫]

April 23, 2020 Gilead人民的希望初步试验失败，被寄予厚望的特效药也没戏了，这和中国早期临床试验结果相似。得了，大家还是关家里熬吧。
April 24, 2020 FDA宣布要谨慎使用羟氯喹治疗新冠肺炎 ，可能对心脏造成风险。

 

[向问天]

没有特效药。
只等疫苗。

 

[lindamy]

羟氯喹也有坏消息？

有，美国法国都有。死亡率高。

但是我认为如果只用于轻症患者，应当是有效的。

将会出更多的对比用药结果。

 

[寻找尼莫]

羟氯喹也有坏消息？

白宫周二辞掉了一位反对羟氯喹的医学背景的官员。
A vaccine expert says he was removed for questioning hydroxychloroquine.
The doctor who led the federal agency involved in developing a coronavirus vaccine said on Wednesday that he was removed from his post after he pressed for rigorous vetting of hydroxychloroquine, an anti-malaria drug embraced by President Trump as a coronavirus treatment, and that the administration has put “politics and cronyism ahead of science.”
Dr. Rick Bright was abruptly dismissed this week as the director of the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, or BARDA, and removed as the deputy assistant secretary for preparedness and response. He was given a narrower job at the National Institutes of Health.
In a scorching statement, Dr. Bright assailed the leadership at the health department, saying he was pressured to direct money toward hydroxychloroquine, one of several “potentially dangerous drugs promoted by those with political connections” and repeatedly described by the president as a potential “game changer” in the fight against the virus.

 

[光放]

有，美国法国都有。死亡率高。

但是我认为如果只用于轻症患者，应当是有效的。

将会出更多的对比用药结果。

为什么轻症患者要冒险用药？

 

[ztbll]

有，美国法国都有。死亡率高。

但是我认为如果只用于轻症患者，应当是有效的。

将会出更多的对比用药结果。

你都从哪看到的这些胡说八道的，那么多一线医生都白说了，这个是目前针对重症相对最有效的，多少个从ICU出来的都证实了。

 

[Seraph72]

有，美国法国都有。死亡率高。

但是我认为如果只用于轻症患者，应当是有效的。

将会出更多的对比用药结果。

用于轻症患者是看不出效果的，因为轻症患者的自愈率很高，就是不吃药不治疗都可以自己恢复，所以轻症患者吃羟氯喹就跟病人吃中药一样，不知道是自己好的还是药起的作用

 

[ztbll]

白宫周二辞掉了一位反对羟氯喹的医学背景的官员。
A vaccine expert says he was removed for questioning hydroxychloroquine.
The doctor who led the federal agency involved in developing a coronavirus vaccine said on Wednesday that he was removed from his post after he pressed for rigorous vetting of hydroxychloroquine, an anti-malaria drug embraced by President Trump as a coronavirus treatment, and that the administration has put “politics and cronyism ahead of science.”
Dr. Rick Bright was abruptly dismissed this week as the director of the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, or BARDA, and removed as the deputy assistant secretary for preparedness and response. He was given a narrower job at the National Institutes of Health.
In a scorching statement, Dr. Bright assailed the leadership at the health department, saying he was pressured to direct money toward hydroxychloroquine, one of several “potentially dangerous drugs promoted by those with political connections” and repeatedly described by the president as a potential “game changer” in the fight against the virus.

福西博士也该给赶走。这些搞疫苗的生怕这个药管用的话，也就没他们啥事了。

 

[lindamy]

你都从哪看到的这些胡说八道的，那么多一线医生都白说了，这个是目前针对重症相对最有效的，多少个从ICU出来的都证实了。

你找出来哪个医生说羟氯喹治重症的我看看

 

[春夏秋鼕]

Stocks close flat after wild session as investors assess Gilead coronavirus treatment

Stocks were taken for a wild ride on Thursday that showed just how important finding a treatment for the coronavirus is for Wall Street.

www.cnbc.com

Stocks quickly cut gains after report says potential Gilead virus treatment flops in trial

Stocks slashed earlier gains on Thursday after a report said Gilead Sciences’ remdesivir flopped in a Chinese trial aimed at treating coronavirus patients.
The Dow Jones Industrial Average was up 116 points, or 0.5%, after jumping more than 400 points earlier in the day. The S&P 500 was up just 0.4% along with the Nasdaq Composite. Both indexes were up more than 1% earlier in the session.
The Financial Times said — citing documents accidentally published by the World Organization — that remdesivir did not improve patients’ condition or reduce the coronavirus pathogen in their bloodstream. Gilead Sciences shares were down more than 3% after a brief volatility halt.
Gildead said that the WHO document had “inappropriate characterisations of the study,” according to the FT. “As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” the company said in a statement.


Stocks surged Friday after STAT News reported that Chicago patients taking remdesivir to treat coronavirus were recovering rapidly from severe virus symptoms.
Equities had initially rallied as crude prices continued their rebound from historic lows.
West Texas Intermediate futures for June delivery jumped 30% to $18 per barrel as traders increased bets on U.S. production cuts. WTI also rallied on Wednesday.
Earlier in the week, concerns over a lack of energy demand sent WTI’s May contract — which expired Tuesday — into a negative price. Crude prices are also down sharply year to date even after their strong gains over the past two days.
“The resulting price action is highly damaging for many oil producers, and certainly implies a sharp fallback in US shale fracking, contributing to much weaker US exports and capex later this year,” wrote Charles Dumas, chief economist at TS Lombard.
Oil’s rebound helped equities claw back some of their steep losses from earlier in the week. Between Monday and Tuesday, the S&P 500 and Dow dropped more than 4% before rallying around 2% on Wednesday.
“Large single day advances can’t alone solve the market’s woes. But they can be part of the solution,” said Frank Cappelleri, executive director at Instinet, regarding Wednesday’s gains.
He noted the average gain for the S&P 500 since the March bottom has been much larger than its average decline. “This kind [of] scenario is what helps bullish patterns succeed and bearish patterns fade away… which is what we’ve seen happen over the last month of trading.”
The major averages have staged a massive rebound since hitting a coronavirus-crisis low on March 23. In that time, the Dow, S&P 500 and Nasdaq are all up over 20%. Still, the major averages remain well below the record highs set in February.
U.S. traders on Thursday also pored through the Labor Department’s latest report on jobless claims.
Another 4.4 million workers filed for unemployment benefits last week, according to data from the Labor Department. That brought the five-week jobless claims total to more than 26 million, erasing all the job gains since the Great Recession. However, Thursday’s print represented a decline from the jobless claims number reported in the previous week.
“The decline in initial jobless claims … is encouraging, but the damage has already been done,” said Paul Ashworth, chief U.S. economist at TS Lombard. He added, however, that the “easing of lockdowns may have pulled some people currently on temporary layoff back into paid employment. If so, then April’s unemployment rate could prove to be the pandemic peak.”
On the earnings front, CSX shares gained more than 3% after the railroad company posted quarterly profits that beat expectations. Union Pacific also got a boost from stronger-than-forecast earnings.
Click here for the latest news on the coronavirus.
Subscribe to CNBC PRO for exclusive insights and analysis, and live business day programming from around the world.

 

[ztbll]

你找出来哪个医生说羟氯喹治重症的我看看

你天天泡网上会不知道？前两天有个民主党的议员自己在电视里说了，这个药救了她的命。这个药的机理就是抑制病毒在体内复制，如果病入膏肓了，当然这种重症是救不回来的。

 

[lindamy]

为什么轻症患者要冒险用药？

有一些对照用药研究表明羟氯喹对轻症患者有疗效，但是对重症有危险。

 

[lindamy]

你天天泡网上会不知道？前两天有个民主党的议员自己在电视里说了，这个药救了她的命。

你自己举证

 

[PAL]

福西博士也该给赶走。这些搞疫苗的生怕这个药管用的话，也就没他们啥事了。

这种思维，服了

 

[ztbll]

有一些对照用药研究表明羟氯喹对轻症患者有疗效，但是对重症有危险。

啥样的算轻，啥样的算重，这个药只能抑制病毒复制，当然不是百分之百有效的。